The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage. Doctors also expect some patients will hesitate to take Leqembi due to its limited impact and potential side effects. They say it will take years to learn how best to deploy the drug and that work must be done to improve diagnosis. “This is the start of a very exciting journey,” said Dr. Ambar Kulshreshtha, a suburban Atlanta family physician focused on dementia patients. More than 6 million Americans, and millions more worldwide, have Alzheimer’s disease, the most common cause of dementia. There’s no cure, but Leqembi clears a sticky brain protein called amyloid that’s a key indicator of Alzheimer’s. Studies showed that it can delay the progression of the disease by a few months when given to people with mild symptoms. Some experts say the delay may be too subtle for patients to notice. |
Boat collision in Canada leaves 3 dead and 5 injured, Ontario police say3 dead, 3 wounded in early morning shooting in Ohio's capitalThe top 10 California colleges where students earn back their tuition within a yearAmerica's first Black astronaut candidate finally goes to space 60 years later on Bezos rocketTens of thousands protest against Mexico's president in the main square of Mexico CityRecord set for most goals in a single season in the Premier LeaguePacers score 39 points in first quarter vs. Knicks to set a Game 7 recordTucker homers twice, ties for lead with 15 as Astros beat Brewers 9Wave of electoral violence in southern Mexico claims 14 lives in matter of daysTikTok's 10 biggest stars